Park West Asset Management’s Elicio Therapeutics ELTX Stock Holding History

Park West Asset Management’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-37,072	Closed	-$301K	–	42
2022 Q4	$301K	Hold	37,072	–	–	0.03%	40
2022 Q3	$341K	Buy	37,072 +29,522	+391%	+$308K	0.02%	50
2022 Q2	$86K	Buy	+7,550	New	+$121K	﹤0.01%	60
2021 Q4	–	Sell	-104,178	Closed	-$10.2M	–	152
2021 Q3	$10.2M	Buy	104,178 +3,549	+4%	+$383K	0.24%	73
2021 Q2	$13M	Buy	100,629 +3,964	+4%	+$572K	0.37%	65
2021 Q1	$17M	Buy	+96,665	New	+$18.7M	0.51%	55

Other funds holding ELTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Park West Asset Management's ELTX Position: Q1 2023 in Review

Park West Asset Management sold out of Elicio Therapeutics (ELTX) in Q1 2023, closing a stake of 37,072 shares — an estimated $301K sold.

Park West Asset Management first reported a position in ELTX in Q1 2021 and held it in 6 quarters. The position peaked at $17M in Q1 2021. 28 funds tracked by Wall St. Rank hold ELTX as of Q1 2023.

Park West Asset Management reported no remaining Elicio Therapeutics position as of Q1 2023 after selling out during the quarter.
Park West Asset Management sold 37,072 Elicio Therapeutics shares in Q1 2023, an estimated $301K.
Park West Asset Management first reported a position in Elicio Therapeutics in Q1 2021 and held it in 6 quarters.
Park West Asset Management's Elicio Therapeutics position peaked at $17M in Q1 2021.
28 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2023.

Based on Park West Asset Management's 13F filing for Q1 2023, filed 15 May 2023.